orm • "AVA-101 back to drawing board," nex= key catalyst may be decision on therapy in 1H afte= preclinical studies completed, lefferies analyst B=ren Amin writes; may also deprioritize its experimenta c=lor blindness programs " PT to $20 vs $51, remains bu= • AAVL 3 buys, 2 holds, 1 sell; avg PT $19=